histogen.com Open in urlscan Pro
35.226.133.80  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * About Histogen
   * Overview
   * Management Team
   * Board of Directors
   * Careers
 * Technology
   * Overview
   * Development Pipeline
 * Investors
 * Contact Us

 * Home
 * About Histogen
   * Overview
   * Management Team
   * Board of Directors
   * Careers
 * Technology
   * Overview
   * Development Pipeline
 * Investors
 * Contact Us


NEW HOME


RESTORING FUNCTION & ENHANCING LIVES



Histogen Inc. is a clinical-stage therapeutics company focused on developing
both potential first-in-class restorative therapeutics that ignite the body’s
natural process to repair and maintain healthy biological function as well as a
pipeline of clinical and preclinical small molecule pan-caspase and caspase
selective inhibitors focused on treatments for infectious and inflammatory
diseases. Under our biologics technology platform, our product candidates in
development are HST-003, a treatment for joint cartilage repair, and HST-004, a
treatment for spinal disc repair. In addition, within our small molecule
pipeline, our product candidates include emricasan, CTS-2090 and CTS-2096.
Currently, emricasan is being developed jointly with our collaboration partner,
Amerimmune, for the treatment of COVID-19, and we are evaluating the use of
emricasan for other infectious diseases including the treatment of MRSA. We also
have preclinical product candidates, CTS-2090 and CTS-2096, novel, potent,
orally bioavailable, and highly selective small molecule inhibitors of caspase-1
designed for the treatment of certain inflammatory diseases.

ABOUT




LATEST NEWS

August 11, 2022

HISTOGEN REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS
UPDATE

Closed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price
Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ:
HSTO), a clinical-stage therapeutics company focused on developing both
restorative therapeutics for orthopedic indications and pan-caspase



Read more

July 27, 2022

HISTOGEN TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDE BUSINESS
UPDATE

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a
clinical-stage therapeutics company focused on developing both restorative
therapeutics and pan-caspase and caspase selective inhibitors focused on
treatments for infectious and inflammatory diseases, today announced that



Read more

July 14, 2022

HISTOGEN ANNOUNCES CLOSING OF $5 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET
UNDER NASDAQ RULES

SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a
clinical-stage therapeutics company focused on developing both restorative
therapeutics and pan-caspase and caspase selective inhibitors focused on
treatments for infectious and inflammatory diseases, announced today that



Read more



View All



© Histogen Inc., CA 92121Disclaimer